Equibles does not estimate personal net worth.
Get an email with a short summary when Arcturus Therapeutics Holdings Inc. publishes a filing, an earnings call transcript or a press release.
Get ARCT alertsAndy Sassine is recorded as Board Member at Arcturus Therapeutics Holdings Inc. (ARCT) since June 14, 2024 and CFO at Arcturus Therapeutics Holdings Inc. (ARCT). The newest filing on record that lists Andy Sassine as CFO at Arcturus Therapeutics Holdings Inc. (ARCT) is dated April 24, 2026. Arcturus Therapeutics Holdings Inc. reported in an 8-K filed December 15, 2025 that Andy Sassine resigned as member of the Company's Board of Directors, effective December 11, 2025. Arcturus Therapeutics Holdings Inc. reported in an 8-K filed December 15, 2025 that Andy Sassine resigned as Chief Financial Officer, effective December 31, 2025. Arcturus Therapeutics Holdings Inc. reported in an 8-K filed June 14, 2024 that Andy Sassine was appointed Director, effective June 14, 2024. The proxy statement of Arcturus Therapeutics Holdings Inc. reports total compensation of $1,181,500 for Andy Sassine in fiscal 2025, including a base salary of $572,000. Disclosed compensation is on record for 8 fiscal years. Andy Sassine has spoken on 12 earnings calls across 1 company, most recently for Arcturus Therapeutics Holdings Inc. on May 12, 2025. Arcturus Therapeutics Holdings Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcturus Therapeutics Holdings Inc. includes Joseph E. Payne (CEO and Board Member), Joseph Payne (CEO and Board Member), Dennis Mulroy (CFO) and 7 others.
“Mr. Sassine also stepped down as a member of the Board on December 11, 2025.”
“On December 11, 2025, Arcturus Therapeutics Holdings, Inc., a Delaware corporation (the "Company") and Andy Sassine, Chief Financial Officer of the Company and a member of the Company's Board of Directors (the "Board"), mutually agreed to end their employment relationship in an amicable manner effective December 31, 2025 (the "Separation Date").”
“The press release issued earlier today includes financial statements for the first quarter of 2025 and summarizes our year-over-year and sequential financial performance.”
“The press release issued earlier today includes financial statements for the second quarter of 2024 and provides a summary and analysis of year-over-year and sequential financial performance.”
“The press release issued earlier today includes financial statements for the fourth quarter and fiscal year ending December 31st, 2023, and provides a summary and analysis of year-over-year financial results.”
“The press release issued earlier today includes financial statements for the second quarter and six months ended June 2023 and provides a summary and analysis of year-over-year financial results.”
“The press release issued earlier today includes financial statements for the first quarter of 2023 and provides a summary and analysis of year-over-year and sequential financial performance.”
2024-06-14–present
Start not stated–present
Last confirmed April 24, 2026
2018-01-01–2025-12-11
Start not stated–2025-12-31
Biotechnology · Healthcare
CFO, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcturus Therapeutics Holdings Inc. (ARCT) | Former Chief Financial Officer | $572,000 | $1,181,500 |
| 2024 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer, Director | $550,000 | $1,618,000 |
| 2023 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer, Director | $550,000 | $2,182,500 |
| 2022 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer, Director | $525,000 | $3,145,375 |
| 2021 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer, Director | $500,000 | $750,000 |
| 2020 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer | $400,000 | $7,654,800 |
| 2019 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer | $375,000 | $1,326,880 |
| 2018 | Arcturus Therapeutics Holdings Inc. (ARCT) | Chief Financial Officer | $120,000 | $246,340 |
